Literature DB >> 2666586

Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse.

K L Owen1, T Shibata, S Izui, S E Walker.   

Abstract

New Zealand Black/New Zealand White (NZB/W) mice, a model of systemic lupus erythematosus (SLE), have age-dependent loss of interleukin-2 (IL-2) production. To determine if replacement therapy would influence the course of autoimmune disease, we injected groups of NZB/W mice with low-dose (1,500 units/day) or high-dose (15,000 units/day) purified human recombinant IL-2. Parameters of active SLE and populations of splenocytes were not altered consistently by long-term treatment with either dose of IL-2.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2666586

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN: 0732-6580


  7 in total

Review 1.  Tumour necrosis factor and other cytokines in murine lupus.

Authors:  A N Theofilopoulos; B R Lawson
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent.

Authors:  Marta E Stremska; Chao Dai; Rajkumar Venkatadri; Hongyang Wang; Vikram Sabapathy; Gaurav Kumar; Sheethal Jose; Saleh Mohammad; Sun-Sang J Sung; Shu Man Fu; Rahul Sharma
Journal:  J Autoimmun       Date:  2019-05-15       Impact factor: 7.094

Review 3.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

Review 4.  Regulatory T cells in acute and chronic kidney diseases.

Authors:  Rahul Sharma; Gilbert R Kinsey
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-06

5.  The effects of CP 17193, an immunosuppressive pyrazaloquinoline, on the development of spontaneous lupus disease in NZBW F1 hybrid mice.

Authors:  R V Bundick; R P Eady
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 6.  Abnormalities in the regulation of variable region genes that encode for antibodies to DNA may be a central factor in the pathogenesis of systemic lupus erythematosus.

Authors:  A K Singh
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

Review 7.  Targeting Regulatory T Cells for Therapy of Lupus Nephritis.

Authors:  Rajkumar Venkatadri; Vikram Sabapathy; Murat Dogan; Rahul Sharma
Journal:  Front Pharmacol       Date:  2022-01-06       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.